TREATMENT WITH EVEROLIMUS LEADS TO CMV-PROTECTION DUE TO INCREASED POTENCY OF CMV-SPECIFIC CD4+T CELLS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS COMPARED TO A STANDARD REGIMEN: 12 MONTHS DATA OF THE ATHENA STUDY

Sester Martina; Marx Stefanie; Sommerer Claudia; Suwelack Barbara; Dragun Duska; Witzke Oliver; Lehner Frank; Kroeger Irena; Junge Martina; Thaiss Friedrich; Nashan Bjoern; Hauser Ingeborg A.

首页> 外文期刊>Transplant international : >TREATMENT WITH EVEROLIMUS LEADS TO CMV-PROTECTION DUE TO INCREASED POTENCY OF CMV-SPECIFIC CD4+T CELLS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS COMPARED TO A STANDARD REGIMEN: 12 MONTHS DATA OF THE ATHENA STUDY

【24h】

TREATMENT WITH EVEROLIMUS LEADS TO CMV-PROTECTION DUE TO INCREASED POTENCY OF CMV-SPECIFIC CD4+T CELLS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS COMPARED TO A STANDARD REGIMEN: 12 MONTHS DATA OF THE ATHENA STUDY

机译：与标准方案相比，everolimus的治疗导致CMV特异性CD4 + T细胞的效力增加，导致CMV特异性CD4 + T细胞的效力增加：12个月的雅典娜研究数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Transplant international :》 |2019年第s2期|共1页
作者
Sester Martina; Marx Stefanie; Sommerer Claudia; Suwelack Barbara; Dragun Duska; Witzke Oliver; Lehner Frank; Kroeger Irena; Junge Martina; Thaiss Friedrich; Nashan Bjoern; Hauser Ingeborg A.;
展开▼
作者单位

Novartis Pharma GmbH Basel Switzerland;

Novartis Pharma GmbH Basel Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类器官移植术;
关键词

相似文献

外文文献
中文文献
专利

1. TREATMENT WITH EVEROLIMUS LEADS TO CMV-PROTECTION DUE TO INCREASED POTENCY OF CMV-SPECIFIC CD4+T CELLS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS COMPARED TO A STANDARD REGIMEN: 12 MONTHS DATA OF THE ATHENA STUDY [J] . Sester Martina, Marx Stefanie, Sommerer Claudia, Transplant international : . 2019,第S2期

机译：与标准方案相比，everolimus的治疗导致CMV特异性CD4 + T细胞的效力增加，导致CMV特异性CD4 + T细胞的效力增加：12个月的雅典娜研究数据
2. Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to Standard Tacrolimus-MPA Regimen in de Novo Kidney Transplant Recipients: Athena 12 months Data on Infections [J] . Dragun Duska, Suwelack Barbara, Sommerer Claudia, Transplantation: Official Journal of the Transplantation Society . 2018,第9Suppla期

机译：基于现代的血管血清的方案的显着抗CMV / BKV效应与Novo肾移植受者的标准Tacrolimus-MPA方案相比：雅典娜12个月的感染数据
3. The Athena Study: 12 Months Safety and Efficacy Data for Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in de Novo Kidney Transplant Patients [J] . Nashan Bjoern, Sommerer Claudia, Suwelack Barbara, Transplantation: Official Journal of the Transplantation Society . 2018,第9Suppla期

机译：雅典娜的研究：12个月内血管司或环孢菌素的安全性和疗效数据与德诺伊肾移植患者的标准Tacrolimus-mycophenolate方案相比联合了他克莫司或环孢菌素
4. Design and rationale of the ATHENA study – A 12-month multicentre prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial [O] . Claudia Sommerer, Barbara Suwelack, Duska Dragun, 2016

机译：ATHENA研究的设计和基本原理–一项为期12个月的多中心前瞻性研究评估了从头进行依维莫司治疗与环孢素或他克莫司减量相较于标准方案在肾移植患者中的治疗效果：随机对照研究方案试用
5. Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial [O] . Sommerer, Claudia, Suwelack, Barbara, Dragun, Duska, 2016

机译：ATHENA研究的设计和基本原理–一项为期12个月的多中心前瞻性研究，评估基于从头依维莫司的方案与环孢素或他克莫司减量相较于标准方案在肾移植患者中的效果：随机对照研究方案试用

TREATMENT WITH EVEROLIMUS LEADS TO CMV-PROTECTION DUE TO INCREASED POTENCY OF CMV-SPECIFIC CD4+T CELLS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS COMPARED TO A STANDARD REGIMEN: 12 MONTHS DATA OF THE ATHENA STUDY

著录项

相似文献

相关主题

期刊订阅